Abstract
AbstractThe DNA damage response (DDR) is an important mechanism to maintain genome integrity by arresting cell cycle progression and inducing DNA repair and/or apoptosis. Therefore, the activity of DDR is closely related to the drug sensitivity of cancer cells. Inhibitors of ATR, a key member of protein kinases functioning in DDR, are attractive candidates as sensitizers in chemotherapy. In this study, we explore another candidate of chemosensitizers and report DNA topoisomerase II binding protein 1 (TopBP1), a regulator of ATR‐mediated signaling, as a potential target to increase the efficacy of chemotherapeutic treatments. Suppression of TopBP1 using siRNA increased cancer cell sensitivity to cisplatin and an alkylating agent N‐methyl‐N‐nitrosourea (MNU), concomitant with a percentage increase in the sub‐G1 population and caspase‐9 activation. The immunoblotting analysis revealed that the phosphorylation of CHK1 was significantly reduced in TopBP1‐knockdown cells. Consequently, treatment with an ATR inhibitor dramatically increased the production of the sub‐G1 population compared to an ATM inhibitor. Phosphorylation of RPA2 increased after drug treatment in TopBP1‐knockdown cells. These results suggest that TopBP1 is involved in DDR protecting stalled forks from collapse and preventing apoptosis through the activation of an ATR/CHK1 signaling pathway.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.